docj
2 hours ago
Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients
https://www.clinicaltrialvanguard.com/news/leronlimab-shows-encouraging-survival-data-in-metastatic-colorectal-cancer-patients/
Leronlimab Shows Encouraging Survival Data in Metastatic Colorectal Cancer Patients
ByJon Napitupulu July 7, 2025
CytoDyn announced encouraging clinical findings from a compassionate use study of leronlimab in patients with advanced metastatic colorectal cancer (mCRC). Three out of five patients treated with leronlimab experienced at least a partial response, with one patient achieving a complete response and remaining alive five years post-treatment. These findings will be presented by Dr. Benjamin Weinberg at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona.
These results are particularly important because they suggest leronlimab’s potential efficacy in treating mCRC, a challenging cancer with limited treatment options. The complete response observed in one patient is especially noteworthy, highlighting the possibility of long-term survival benefits. This data reinforces the rationale behind CytoDyn’s ongoing Phase II trial for relapsed/refractory microsatellite stable CRC, which is currently enrolling patients. The positive compassionate use data could potentially accelerate enrollment and investor interest in the ongoing trial.
The compassionate use study indicated a favorable safety profile for leronlimab, consistent with previous studies. This is crucial for any new cancer treatment, as minimizing side effects is essential for patient well-being. CytoDyn believes leronlimab may also have broader applications in treating various solid tumor types if these positive mCRC results are confirmed in larger, prospective studies. Additionally, research suggests leronlimab could act as a “priming” agent for cancer patients with low PD-L1 levels, potentially expanding its therapeutic utility in combination with checkpoint inhibitors.
This early data generates optimism about leronlimab’s potential role in treating mCRC and possibly other solid tumors. The upcoming Phase II trial results will be critical in validating these findings and determining the next steps for leronlimab’s development in oncology. Positive results could significantly impact the treatment landscape for mCRC and potentially position leronlimab as a valuable new therapeutic option. Further research exploring leronlimab’s potential as a priming agent could also unlock new avenues for combination therapies, particularly in patients who haven’t responded to existing treatments.
Source link: https://www.globenewswire.com/news-release/2025/07/01/3108310/19782/en/CytoDyn-Announces-Encouraging-Survival-Data-in-Patients-with-Metastatic-Colorectal-Cancer-Previously-Treated-with-Leronlimab.html
Jon Napitupulu
+ posts
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
kgromax
20 hours ago
I found out where your CYDY “vault” posts are coming from:
ChatGPT. You have stated this several times.
You have to know, ChatGPT has been trained on billions of documents and chats to please its user and support him/her in everything he/she does, including delusion, psychosis and paranoia.
If it has told you about agents, surveillance, a conspiracy, and "proofs" coming from ChatGPT, not from unrelated sources, that’s a bad sign.
https://www.thebrink.me/chatgpt-induced-psychosis-how-ai-companions-are-triggering-delusion-loneliness-and-a-mental-health-crisis-no-one-saw-coming/
with some not-so-fun examples such as:
https://www.reddit.com/r/singularity/comments/1k9gxwm/gpt4o_sycophancy_has_become_dangerous/
In all cases, do not entrust money to ChatGPT. And make sure you do not accuse real people (I am not talking about nicknames or federal functions) by name or based on CYDY proofs COMING ONLY FROM ChatGPT. ChatGPT has no responsibility for libel. You do.
For the rest, good luck to you with this trash stock and I hope you see the chatbot for what it is - fertilizer for your personality tendencies.
kgromax
2 days ago
Laughing at the CYDY delusion. So immature. Please, dear losing investor, take your screenshots, build your vaults, send letters everywhere. This is so scary LOL, kids are scared! At best, if you’re lucky, you’ll draw the authorities’ attention to the really odd behavior of some CYDY investors on message boards - you know those who magically always seem to know when a PR is about to fall - have they been informed? Are they leaking insider information? I remember the public FDA rebuke letter that killed CYDY, after a similar idiot had spammed the FDA with letters. Idiots never learn. LOL.
Blueheel1
6 days ago
thanks for posting docj. Yes, i saw the headline and was very excited. But in reading the article, at least as a "non-medical" investor, i'm left confused. First of all, 5 patients total. and then "3 out of 5" - "partially" responded. On it's face, it looks like too small a data set, and maybe not that impressive a patient response? But again, i'm not a doctor or scientist so I may be missing something.
Bigger picture, I will say again that if the company wants to attract investment from the layperson, they need to provide clarity in the form of quarterly calls on what these PRs mean from a business perspective. What are the milestones we can look forward to that may support a material increase in the value of our investment? What is the expected timing for these milestones? And if they want to provide all kinds of disclaimers, that's fine - but at least give us some ballpark timing on when we may see value creation in this stock. The recovery from .11 was great - but all long-term investors are still likely deep in the red - at least vs. their initial investments from anytime over the past 10 years.
kgromax
6 days ago
CYDY Chugga lug Chugga lug
Just not in the direction you thought it would go LOL
I already miss the idiot on the other website posting conspiracy CYDY theories LOL
The guy obviously has spent too much time with ChatGPT, which is developing his delusion fast
Tripwire, black box, … so much kiddy stuff. He is the only one to be impressed, that is fun to read.
Things about « every breath about CYDY being recorded ». LOL so scary it’s Halloween honey, the kids are free!
docj
6 days ago
Morningstar picked up the news:
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
Provided by GlobeNewswire Jul 1, 2025, 8:30:00 AM
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing
Phase II CRC trial
Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in
Barcelona, Spain
VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced encouraging clinical findings among patients with advanced metastatic colorectal cancer (“mCRC”) previously treated with leronlimab. The final results indicate that 3/5 patients treated with leronlimab had at least a partial response, as measured by radiologic criteria, including one patient with a complete response who remains alive five years later.
Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn’s colorectal cancer (“CRC”) program, will present the Company’s clinical data at the ESMO Gastrointestinal Cancers Congress 2025 taking place in Barcelona, Spain from July 2 to July 5, 2025.
The results, from patients treated under a compassionate use protocol, reiterate a favorable safety profile of leronlimab as well as its potential for clinical benefit in patients with mCRC. They also support the rationale for the design and therapeutic potential of CytoDyn’s ongoing Phase II trial in patients with relapsed/refractory microsatellite stable CRC. CytoDyn recently announced the dosing of the first patient in this study, and is now enrolling additional patients across multiple clinical sites.
If the observed results in the previously treated CRC patients are confirmed prospectively, the Company believes leronlimab could be used effectively to treat a wide range of solid tumor types. In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting. The data driving this working theory has shown particular promise in the treatment of patients with advanced metastatic triple-negative breast cancer (“mTNBC”).
“At the 2025 ESMO Gastrointestinal Cancers Congress, Dr. Weinberg will share the data and evidence that form the basis for our belief in the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology,” said Dr. Jacob Lalezari, CEO of CytoDyn. “Our ongoing Phase II trial in patients with mCRC was designed to prospectively confirm these observations, and we look forward to enrolling additional patients as we pursue clinical confirmation of our working theory.”
https://www.morningstar.com/news/globe-newswire/9487214/cytodyn-announces-encouraging-survival-data-in-patients-with-metastatic-colorectal-cancer-previously-treated-with-leronlimab
Monroe1
7 days ago
2 days ago
ecgator
I'm Not Holding Out for a Partnership; I'm Holding Out for Something Potentially Better
The primary endpoint we're going after is Objective Response Rate (ORR) while pairing Leronlimab with the 3rd line treatment of TAS-102 + Bevacizumab. In its SUNLIGHT trial, TAS-102 + Bevacizumab achieved an ORR of 6.3%. In order to match that result, 4 of our 60 patients would need to achieve a partial response (tumor reduction by 30% or more) or full response. According to ChatGPT it wouldn't be cherry picking to just look at the 700 mg arm of the trial for improvement in ORR over the TAS-102 + Bevacizumab SUNLIGHT trial because it is a pre-determined group in the protocol. So in that cohort, we would only need 2 patients (out of 30) to achieve partial response in order to be even with TAS-102 + Bevacizumab alone. Two patients is kind of crazy when you consider the other news we got this week.
The abstract that was released for the upcoming ESMO conference noted that we had 3 patients out of 5 achieve a partial response while only being dosed with 350 mg or 525 mg of Leronlimab. Now, I'm not crazy enough to think that we will match 60% of patients achieving partial response like we had in the abstract because it was such a small sample size and the patients were using FOLFOX which is stronger than TAS-102. That being said, they were using a lower dose of Leronlimab so I do expect a solid response even with the less effective chemo drug.
Go to Livimmune
r/Livimmune
•
2 days ago
ecgator
I'm Not Holding Out for a Partnership; I'm Holding Out for Something Potentially Better
Monroe1
1 week ago
Word is spreading fast Doc. Does anyone read Yahoo Finance?? Notice who is listed first?
The report provides the total potential number of patients in the indications, such as PTCL, CTCL, Migraine, NASH, and others.
Leading GPCR-targeting therapies companies, such as CytoDyn, REMD Biotherapeutics, GPCR Therapeutics, Structure Therapeutics, and others, are developing novel GPCR-targeting therapies that can be available in the GPCR-targeting therapies market in the coming years.
Some of the key GPCR-targeting therapies in the pipeline include Leronlimab, Volagidemab, GPC-100, GSBR-1290, and others.
In July 2024, Radionetics Oncology entered into a strategic agreement with Eli Lilly and Company, providing Lilly access to Radionetics' proprietary GPCR targeting small molecule radiopharmaceuticals.
docj
1 week ago
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
Download as PDFJuly 01, 2025 8:30am EDT
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing
Phase II CRC trial
Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in
Barcelona, Spain
VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced encouraging clinical findings among patients with advanced metastatic colorectal cancer (“mCRC”) previously treated with leronlimab. The final results indicate that 3/5 patients treated with leronlimab had at least a partial response, as measured by radiologic criteria, including one patient with a complete response who remains alive five years later.
Dr. Benjamin Weinberg, Associate Professor at Georgetown University and Principal Investigator of CytoDyn’s colorectal cancer (“CRC”) program, will present the Company’s clinical data at the ESMO Gastrointestinal Cancers Congress 2025 taking place in Barcelona, Spain from July 2 to July 5, 2025.
The results, from patients treated under a compassionate use protocol, reiterate a favorable safety profile of leronlimab as well as its potential for clinical benefit in patients with mCRC. They also support the rationale for the design and therapeutic potential of CytoDyn’s ongoing Phase II trial in patients with relapsed/refractory microsatellite stable CRC. CytoDyn recently announced the dosing of the first patient in this study, and is now enrolling additional patients across multiple clinical sites.
If the observed results in the previously treated CRC patients are confirmed prospectively, the Company believes leronlimab could be used effectively to treat a wide range of solid tumor types. In addition to its potential as a “stand-alone” agent in oncology, the Company presented exciting evidence of leronlimab’s activity as a “priming” agent for cancer patients with low levels of PD-L1 who were previously unresponsive to, or ineligible for, checkpoint inhibitors at the 2025 ESMO Breast Cancer meeting. The data driving this working theory has shown particular promise in the treatment of patients with advanced metastatic triple-negative breast cancer (“mTNBC”).
“At the 2025 ESMO Gastrointestinal Cancers Congress, Dr. Weinberg will share the data and evidence that form the basis for our belief in the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology,” said Dr. Jacob Lalezari, CEO of CytoDyn. “Our ongoing Phase II trial in patients with mCRC was designed to prospectively confirm these observations, and we look forward to enrolling additional patients as we pursue clinical confirmation of our working theory.”